PACB

In the past six months, PACB's stock price increased by 52.32% over the last year, trading at approximately $2.33 per share as of October 2026. Key events included the Q1 2026 Earnings Conference Call on May 7, 2026, and participation in the Jefferies Global Healthcare Conference on June 4, 2026. On August 3, 2026, PacBio reported Q2 2026 financial results, with revenue and adjusted loss missing analyst forecasts; however, the global commercial rollout of SPRQ-Nx chemistry contributed to optimism and increased demand. The company also presented at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. In late September 2026, the stock surged significantly following the announcement of a five-year contract with the U.S. Department of Veterans Affairs and a partnership with DNAstack, highlighting increasing demand for its HiFi sequencing technology. The launch of EpiSign METRIC 5-base on October 1, 2026, caused an approximate 30% surge in the stock price. On October 6, 2026, CFO James R. Gibson II sold over $2 million worth of company stock. UBS Group initiated coverage on September 9, 2026 (reported October 8, 2026), with a 'neutral' rating and a $1.35 price target, which contributed to a 12.78% stock price drop. Additionally, PacBio revised its full-year outlook downward, indicating a delay in achieving cash flow breakeven.